Warfarin: The End or the End of One Size Fits All Therapy?
AbstractOral anticoagulants are required for both treatment and prophylaxis in many different diseases. Clinicians and patients now have a choice of oral anticoagulants, including the vitamin K antagonists (of which warfarin is the most widely used and is used as the exemplar in this paper), and direct oral anticoagulants (DOACs: dabigatran, apixaban, rivaroxaban, and edoxaban). This paper explores the recent advances and controversies in oral anticoagulation. While some commentators may favour a complete switchover to DOACs, this paper argues that warfarin still has a place in therapy, and a stratified approach that enables the correct choice of both drug and dose would improve both patient outcomes and affordability. View Full-Text
Share & Cite This Article
Pirmohamed, M. Warfarin: The End or the End of One Size Fits All Therapy? J. Pers. Med. 2018, 8, 22.
Pirmohamed M. Warfarin: The End or the End of One Size Fits All Therapy? Journal of Personalized Medicine. 2018; 8(3):22.Chicago/Turabian Style
Pirmohamed, Munir. 2018. "Warfarin: The End or the End of One Size Fits All Therapy?" J. Pers. Med. 8, no. 3: 22.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.